Neo Medical – a Swiss technology company specializing in spine surgery – announced the successful completion of its Series B financing round, including the conversion of existing shareholder loans. And with this funding round, Neo has secured an additional equity investment of up to $68 million (CHF 58 million) to accelerate its global growth.
Led by Gyrus Capital SA (Gyrus), along with the participation of existing investors, including founders Vincent Lefauconnier and Jonas Larsson, this landmark round is one of the most significant in the spine industry in the last decade.
The funding proceeds will increase Neo’s market share in key regions with an immediate focus on expanding the US business, deploying new, complementary, and disruptive products, and enhancing the capabilities of its unique AI-driven augmented reality intraoperative data platform ADVISE. Through ADVISE, the company’s portfolio of advanced surgical technologies – Neo Universal – represents a major step forward for the $7.6 billion global thoracolumbar fusion market.
Since its commercial launch in 2016, Neo’s technologies have been used to treat around 36,000 patients, and the company has made significant progress in both operational and clinical performance compared to traditional standards. And studies have shown Neo’s products can cut implant failure rates by up to three-times, infection risk by half, and time spent in surgery by up to 29%, reducing the need for revisionary surgery by as much as 50%.
KEY QUOTES:
“Thoracolumbar spine surgery is a large market that has lacked disruptive innovation for decades – the spine sector needs innovation to improve patient outcomes and drive positive change for all stakeholders. This is precisely what we have set out to achieve with Neo Universal – a platform introducing new technological and structural approaches to create real value both inside and outside the operating theatre. After successfully entering key markets, we are ready to scale. This funding will enable us to grow and push the boundaries of what is possible in spine surgery, bringing our solutions to more healthcare providers and, most importantly, improving outcomes for patients.”
“This raise is the next step in solidifying Neo Universal as one of the premier solutions on the market. Intended to treat thoracolumbar patients in inpatient and outpatient settings, it supports both MIS and open approaches. Launching extended capabilities for complex surgery will soon optimize our platform coverage from ambulatory surgery to ever more complex trauma and deformity.”
-Vincent Lefauconnier, Neo Medical’s CEO and Co-Founder
“Neo Medical’s vision and product platform has already proven itself in Europe and is poised to expand rapidly in the US. The sustainable commercialization of Neo’s integrated portfolio of technologies and innovative service model strategically positions the company to scale and capitalize on evolving market trends, including within outpatient centers. We are excited to partner with the management team and support Neo’s vision in redefining patient care.”
-Dr. Robert Watson, Partner and Co-Founder of Gyrus
